<DOC>
	<DOCNO>NCT03041038</DOCNO>
	<brief_summary>The ichthyoses group lifelong genetic disorder share characteristic generalize skin thickening , scale underlie cutaneous inflammation . There therapy base grow understanding cause disease . However , recent discovery mark elevation expression interleukin-17A ( IL-17A ) IL-17-related cytokine skin individual ichthyosis , may explain inflammation . Investigators propose IL-17-targeting therapeutic safely suppress inflammation possibly feature ichthyosis , improve quality life .</brief_summary>
	<brief_title>The Efficacy Safety Secukinumab Patients With Ichthyoses</brief_title>
	<detailed_description>The ichthyoses group lifelong genetic disorder share characteristic generalize skin thickening , scale underlie cutaneous inflammation . The vast majority orphan disorder associate extremely poor quality life relate social ostracism alter appearance , associate itchiness discomfort , functional limitation skin disease . Among common orphan disorder autosomal recessive congenital ichthyosis ( ARCI ) phenotypic subset lamellar ichthyosis ( ARCI-LI ) congenital ichthyosiform erythroderma ( ARCI-CIE ) , epidermolytic ichthyosis ( EI ) Netherton syndrome ( NS ) . Therapy time-consuming patient parent supportive , focus clearance scaling . There therapy base grow understanding cause disease . There recent discovery mark elevation expression interleukin-17A ( IL-17A ) IL-17-related cytokine skin individual ichthyosis , may explain inflammation . Psoriasis , another inflammatory skin disorder redness scaling , show result IL-17 pathway activation IL-17A inhibition effective therapy know treat psoriasis . Investigators propose IL-17-targeting therapeutic safely suppress inflammation possibly feature ichthyosis , improve quality life . In long-term , open-label extension , Investigators propose treat adult ichthyosis least moderate erythema subcutaneously administer anti-IL-17 antibody ( secukinumab ) serially assess clinical response therapy safety .</detailed_description>
	<mesh_term>Ichthyosis</mesh_term>
	<mesh_term>Ichthyosis , Lamellar</mesh_term>
	<mesh_term>Netherton Syndrome</mesh_term>
	<mesh_term>Ichthyosiform Erythroderma , Congenital</mesh_term>
	<mesh_term>Dermatitis , Exfoliative</mesh_term>
	<mesh_term>Hyperkeratosis , Epidermolytic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject provide informed consent Subjects least 18 year age old time screen Female subject must pregnant breastfeed Female subject childbearing potential negative urine pregnancy test use least one form contraception ( abstinence allow ) Subjects must confirm diagnosis ARCI ( divide phenotypically ARCILI ARCICIE ) , EI NS ( genotype willingness genotyped ) Subjects must clinically judge immunocompetent . Subjects allergy secukinumab component product . Subjects normal baseline laboratory testing ( CMP , CBC , HIV negative , hepatitis B , C negative , QuantiFERONÂ®TB gold negative ) Subjects must erythema score least 18 IASI IASIE score 12 ( least moderate severity erythema ) baseline Subjects unable give inform consent assent . Subjects without confirm diagnosis ARCI , EI , NS . Subjects know allergy secukinumab . Female subject pregnant , consider become pregnant , breastfeed . Subjects prior biologic use target IL17A/IL17 receptor A IL12/IL23 prior use TNFalpha blocker . Subjects use systemic retinoid within one month prior initiation . Subjects use topical retinoids keratolytics within one week prior initiation . Subjects use emollient area biopsied previous 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>